Professor Persis Amrolia and Dr. Sara Ghorashian at Great Ormond Street Hospital (GOSH) and the UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) led the CARPALL trial, in which they tested a new CAR T-cell therapy in children and young adults with previously incurable acute lymphoblastic leukemia (ALL).
Medical Xpress reports that, “In this approach, the patient’s own T cells are genetically modified to contain a new type of CAR molecule known as CAT-19, which was developed in Dr. Martin Pule’s laboratory at the UCL Cancer Institute.”
Published in Nature Medicine today, the results show that after receiving the CAR T treatment, 12 out of 14 patients with otherwise incurable ALL cleared their disease after three months and five patients remain leukemia-free.
What an accomplishment. These kinds of studies show the true potential of using one’s immune system to target and fight off cancer cells. Some of these children and adults may have given up hope in their fight against cancer, but herein lies the importance of offering clinical trials as a treatment option; it literally saves lives.
Call to Action: Remain informed on new CAR T-cell therapies with TrialSite News’ concierge services. You may also learn more about the CARPALL Trial, which is currently recruiting participants, here.